Industry Could Be Made To Pay For Stronger HTA Cooperation in EU
Executive Summary
The European Commission wants to strengthen EU cooperation in the area of health technology assessment. Among the options it is considering are mandatory and voluntary participation models… and charging medical device and drug companies fees.
You may also be interested in...
€20m Action Tackles Poor Uptake Of Joint HTAs Across Europe; Commission Consultation Nears
Europe’s EUnetHTA collaboration is working on producing a raft of new joint HTA reports for medical device and drug developers, and it is planning to facilitate 35 early dialogues between HTA bodies and manufacturers. It is also exploring why only a few European countries are making full use of the reports it has produced so far. Meanwhile, the European Commission is gearing up to consult extensively on how to create a sustainable network for HTAs across Europe.
As Appraisal Fees Loom, NICE Says No To Industry Calls For Reform
A proposal by the UK's HTA body NICE to charge companies for technology appraisals has raised several issues, such as the need for reforms to the HTA process, ensuring independence and credibility of appraisals, greater accountability and transparency at NICE, and the impact of fees on bringing new medicines to market.
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.